Key takeaways
- Zepbound and Mounjaro are the same drug. Both contain tirzepatide in the same listed strengths (Mounjaro label, Zepbound label).
- The approved use differs. Mounjaro is labeled for type 2 diabetes, Zepbound for weight reduction and sleep apnea (Zepbound label).
- Tirzepatide beat semaglutide for weight. 20.2% vs 13.7% at 72 weeks in adults with obesity and no diabetes, in an open-label trial (Aronne et al., 2025).
- Both carry the thyroid C-cell boxed warning. Neither suits people with medullary thyroid carcinoma or MEN 2 (Zepbound label).
- Compounded tirzepatide is not Zepbound. The FDA does not verify compounded drugs before marketing (FDA).
Short Answer
Are Zepbound and Mounjaro the Same Drug?
Zepbound and Mounjaro are the same drug, and the Zepbound vs Mounjaro difference is only the approved use: both contain tirzepatide, a once-weekly injection, and each brand is approved in the conditions the FDA approved each brand to treat. Mounjaro's label lists type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes at high risk, while Zepbound's label lists weight reduction and moderate to severe obstructive sleep apnea in adults with obesity.
So is Zepbound the same as Mounjaro? Yes, at the molecular level. Both labels describe tirzepatide as a GIP receptor and GLP-1 receptor agonist, and both list the same pen and vial strengths, from 2.5 mg to 15 mg (Mounjaro, Zepbound). The FDA approved Zepbound on November 8, 2023 for chronic weight management in adults with obesity or overweight and at least one weight-related condition. The brand name tells you what the prescription was written for, not what is in the pen.
Disclosure: Protocol Health prescribes compounded tirzepatide in clinician-supervised medical weight loss, so we have a commercial interest in this topic. Every clinical claim below links to a drug label, a trial or an FDA page so you can check our reading yourself.
So Zepbound and Mounjaro are one drug sold under two names, and the name follows the approved use.
Difference
What Is the Difference Between Zepbound and Mounjaro?
The difference between Zepbound and Mounjaro is the approved use, because each brand carries a different FDA-labeled indication for the same active ingredient. Mounjaro's label also covers children 10 and older with type 2 diabetes, while Zepbound's indications are written for adults (Mounjaro label, Zepbound label).
| Feature | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Labeled use | Type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes at high risk | Weight reduction and maintenance in adults with obesity or overweight plus a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity |
| Who the label covers | Adults and children 10 and older (type 2 diabetes) | Adults |
| Boxed warning | Risk of thyroid C-cell tumors | Risk of thyroid C-cell tumors |
| Strengths listed | 2.5 mg to 15 mg | 2.5 mg to 15 mg |
| Maker | Eli Lilly | Eli Lilly |
The sleep apnea indication is the clearest example of a Zepbound-only use. In two trials of adults with moderate to severe obstructive sleep apnea and obesity, tirzepatide lowered the apnea-hypopnea index by 25.3 events per hour versus 5.3 with placebo in the first trial, as reported in SURMOUNT-OSA. Our guide to tirzepatide for weight loss covers the weight-loss trials in more depth.
So the practical difference between Mounjaro and Zepbound is paperwork and indication, and the drug inside is identical.
How It Works
How Does Tirzepatide Work in Zepbound and Mounjaro?
Tirzepatide works in Zepbound and Mounjaro by activating two gut-hormone receptors, GIP and GLP-1, that help regulate appetite and calorie intake. The Zepbound label states that GLP-1 is a physiological regulator of appetite and caloric intake, and that nonclinical studies suggest adding GIP may further contribute to the regulation of food intake.
Semaglutide, the drug in Ozempic and Wegovy, is a selective GLP-1 receptor agonist, which is why tirzepatide is called a dual agonist. We compare the two head to head in tirzepatide vs semaglutide.
The label also says tirzepatide lowers body weight with greater fat mass loss than lean mass loss. That is not the same as sparing muscle, and our guide to GLP-1 medicines and muscle loss explains why protein and resistance training matter.
So tirzepatide is one dual-receptor molecule, and Zepbound and Mounjaro are two labels for it.
Weight Loss
Is Zepbound Better Than Mounjaro for Weight Loss?
Zepbound is not better than Mounjaro for weight loss in any pharmacologic sense, because both deliver tirzepatide and the weight-loss evidence belongs to the molecule. In SURMOUNT-1, 2,539 adults with obesity but without diabetes lost a mean of 15.0%, 19.5% and 20.9% of body weight at 72 weeks on 5 mg, 10 mg and 15 mg, against 3.1% on placebo. Adverse events caused discontinuation in 4.3%, 7.1% and 6.2% of the tirzepatide groups and 2.6% of the placebo group.
Against semaglutide, SURMOUNT-5 randomized 751 adults with obesity but without diabetes to the maximum tolerated dose of either drug for 72 weeks. Weight fell 20.2% with tirzepatide and 13.7% with semaglutide. SURMOUNT-1 was double-blind and SURMOUNT-5 was open-label, and Eli Lilly funded both, so read them as strong but industry-funded evidence. These results describe brand-name tirzepatide; compounded tirzepatide was not studied in them.
Stopping matters as much as starting. In SURMOUNT-4, people who reached a mean 20.9% loss and were then switched to placebo regained 14.0% over 52 weeks, while those who continued tirzepatide lost a further 5.5%. If you are comparing Mounjaro vs Zepbound weight loss results online, the useful question is whether the drug is being taken, not which brand is on the box.
So Zepbound or Mounjaro will not change the weight-loss result, and tirzepatide itself is the variable that the trials measured.
Side Effects
What Are the Side Effects of Zepbound vs Mounjaro?
The side effects of Zepbound and Mounjaro are mostly gastrointestinal, and both labels list nausea, diarrhea, vomiting, constipation, abdominal pain and dyspepsia among their most common reactions (Mounjaro's table uses a 5% threshold, Zepbound's a 2% threshold above placebo). Mounjaro's list adds decreased appetite, and Zepbound's list adds injection site reactions, fatigue, hypersensitivity reactions, belching, hair loss and gastroesophageal reflux disease.
Zepbound vs Mounjaro side effects cannot be ranked from those lists, because they come from different trials in different populations and are not a head-to-head comparison. In SURMOUNT-1, most gastrointestinal events were mild to moderate and occurred mainly during dose escalation (Jastreboff et al., 2022).
Both labels advise patients on oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose escalation (Mounjaro, Zepbound). For alcohol and nausea, see our guide to tirzepatide and alcohol.
So expect the same gastrointestinal pattern from either brand, and report persistent vomiting or severe abdominal pain to your prescriber.
Safety
Is Zepbound or Mounjaro Safe?
Zepbound and Mounjaro carry the same boxed warning, so neither is safe for everyone. The labels state that tirzepatide causes thyroid C-cell tumors in rats, that it is unknown whether it does so in humans, and that it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
The Zepbound label also lists warnings for acute pancreatitis, hypersensitivity reactions, hypoglycemia, diabetic retinopathy complications in people with type 2 diabetes, and pulmonary aspiration during anesthesia or deep sedation. It states that tirzepatide may cause fetal harm and should be stopped when pregnancy is recognized. The Zepbound label also lists acute gallbladder disease among its warnings.
A prescriber screens for these risks before the first injection. Our safety information page explains how Protocol Health approaches screening and monitoring.
So tirzepatide is an effective medicine with real risks, and the safety question is about the person, not the brand.
FDA Status
Is Mounjaro FDA Approved for Weight Loss?
Mounjaro is not FDA approved for weight loss, because its label lists type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes, while Zepbound is the tirzepatide product approved for weight management. A prescriber may still choose Mounjaro for weight when it is medically appropriate, which the FDA describes as prescribing an approved drug for an unapproved use, commonly called off-label.
The FDA notes that for an approved use, the agency has evaluated benefits and risks and the label tells prescribers how to use the drug safely. Off-label use carries no such review for that use. Our guide to how to get tirzepatide walks through the legitimate prescribing routes.
So Zepbound is the on-label choice for weight loss, and Mounjaro for weight loss is a prescriber's judgment call.
Switching
Can You Take Zepbound and Mounjaro Together or Switch Between Them?
You should never take Zepbound and Mounjaro together, because the Zepbound label says that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. Taking both would duplicate the same drug.
A prescriber can move you from one brand to the other, and because both labels list the same strengths, the molecule does not change (Mounjaro, Zepbound). The schedule and strength are decisions for your prescriber, and this article sets none. Moving from a different drug is a separate question, covered in switching from semaglutide to tirzepatide.
So the choice between Zepbound or Mounjaro is a prescribing decision, and combining them is never part of it.
Compounded
Is Compounded Tirzepatide the Same as Zepbound or Mounjaro?
Compounded tirzepatide is not the same as Zepbound or Mounjaro, because the FDA states that compounded drugs are not FDA-approved and the agency does not verify their safety, effectiveness or quality before they are marketed. Zepbound and Mounjaro are approved finished products with reviewed labeling.
On December 19, 2024 the FDA determined the tirzepatide injection shortage was resolved. The agency has also warned of fraudulent compounded semaglutide and tirzepatide, and of dosing errors reported with compounded products. For that reason, ask any clinic whether a prescription would be brand-name or compounded and which state-licensed pharmacy fills it. Our comparison of compounded vs brand-name GLP-1 medicines lays out the differences.
So compounded tirzepatide is a separate, unapproved category, and the same word on a label does not mean the same product.
At Protocol Health
Tirzepatide at Protocol Health
Tirzepatide at Protocol Health starts with an evaluation, not a brand decision. A clinician reviews your history, medications and goals, may order baseline blood work, and decides whether tirzepatide is appropriate as part of medical weight loss.
If we prescribe, we tell you whether it would be a brand-name or a compounded product and which pharmacy fills it. Protocol Health prescribes compounded tirzepatide, which is not FDA-approved, and we have a commercial interest in that service. We do not set doses in articles.
To start, take the Protocol Health quiz and a clinician will follow up.
So tirzepatide at Protocol Health is evaluation first, with the brand-or-compounded question answered plainly before you decide.
Bottom Line
The Bottom Line
Zepbound and Mounjaro are one drug with two labels.
- Same molecule. Both contain tirzepatide in the same listed strengths (Mounjaro, Zepbound).
- Different approved use. Mounjaro is labeled for type 2 diabetes, Zepbound for weight and sleep apnea (Zepbound label).
- Weight results track the drug. Tirzepatide beat semaglutide, 20.2% to 13.7% at 72 weeks in an open-label trial of adults without diabetes (Aronne et al., 2025).
- Never combine them. The Zepbound label advises against other tirzepatide products (label).
- Compounded is not the same. The FDA does not review compounded drugs before they are marketed (FDA).
FAQ
Frequently Asked Questions
Is Zepbound the same as Mounjaro?
Yes, both contain tirzepatide. They differ in approved use: Mounjaro is labeled for type 2 diabetes and Zepbound for weight reduction and obstructive sleep apnea (Mounjaro label, Zepbound label).
Which is stronger, Zepbound or Mounjaro?
Neither. Both labels list the same strengths of the same drug, from 2.5 mg to 15 mg (Mounjaro, Zepbound).
Can you take Zepbound and Mounjaro together?
No. The Zepbound label says coadministration with other tirzepatide-containing products is not recommended.
Can Mounjaro be prescribed for weight loss?
A prescriber can do so off-label, but Mounjaro is not FDA approved for weight loss. The FDA says providers may prescribe approved drugs for unapproved uses when medically appropriate.
Is Zepbound approved for sleep apnea?
Yes, for moderate to severe obstructive sleep apnea in adults with obesity (Zepbound label). In SURMOUNT-OSA, tirzepatide lowered the apnea-hypopnea index versus placebo.
Is compounded tirzepatide the same as Zepbound?
No. Compounded drugs are not FDA-approved, so the FDA does not verify their safety, effectiveness or quality before they are marketed.
Explore
Related at Protocol Health
Talk to a provider about medical weight lossMedical disclaimer
This article is for education only and is not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, stopping, or changing any medication.
Important safety information
Compounded medications are not FDA-approved and are not the same as brand-name products.
References
- Eli Lilly and Company. MOUNJARO (tirzepatide) injection, prescribing information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- U.S. Food and Drug Administration, 2023. FDA Approves New Medication for Chronic Weight Management. Press announcement, November 8, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
- Malhotra A et al., 2024. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. PMID 38912654. https://pubmed.ncbi.nlm.nih.gov/38912654/
- Frias JP et al., 2021. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. PMID 34170647. https://pubmed.ncbi.nlm.nih.gov/34170647/
- Jastreboff AM et al., 2022. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. PMID 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Aronne LJ et al., 2025. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. PMID 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/
- Aronne LJ et al., 2024. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. PMID 38078870. https://pubmed.ncbi.nlm.nih.gov/38078870/
- U.S. Food and Drug Administration. Understanding Unapproved Use of Approved Drugs "Off Label". https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Show all 12 references
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (tirzepatide shortage resolved, 12/19/2024). https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Why trust our physicians
Every article is reviewed by a licensed physician on our medical team and is kept current by our editorial team. Read our editorial policy and our medical review process.
- Medically reviewed by
- Richard Dentico, MD on
- Written by
- Protocol Health Editorial Team
- First published
- Last updated
See an error? Email care@protocolhealthmd.com and we will review it.
More on Weight Loss
- Weight Loss Clinic in California: How Telehealth Weight Loss Works
- Semaglutide Side Effects: What Is Common, What Is Serious and How Long They Last
- Semaglutide Hair Loss: Why It Happens and What It Means
- Switching From Semaglutide to Tirzepatide: How It Works and What to Expect
